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Background: The peptide Paulistine was isolated from the venom of wasp Polybia paulista. This peptide exists
under a natural equilibrium between the forms: oxidised — with an intra-molecular disulphide bridge; and
reduced — in which the thiol groups of the cysteine residues do not form the disulphide bridge. The biological
activities of both forms of the peptide are unknown up to now.
Methods:Both forms of Paulistinewere synthesised and the thiol groups of the reduced formwereprotectedwith
the acetamidemethyl group [Acm-Paulistine] to prevent re-oxidation. The structure/activity relationships of the
two forms were investigated, taking into account the importance of the disulphide bridge.
Results: Paulistine has a more compact structure, while Acm-Paulistine has a more expanded conformation. Bio-
assays reported that Paulistine caused hyperalgesia by interacting with the receptors of lipidmediators involved
in the cyclooxygenase type II pathway, while Acm-Paullistine also caused hyperalgesia, but mediated by recep-
tors involved in the participation of prostanoids in the cyclooxygenase type II pathway.
Conclusion: The acetamidemethylation of the thiol groups of cysteine residues caused small structural changes,
which in turn may have affected some physicochemical properties of the Paulistine. Thus, the dissociation of
the hyperalgesy from the edematogenic effect when the actions of Paulistine and Acm-Paulistine are compared
to each othermay be resulting from the inﬂuence of the introduction of Acm-group in the structure of Paulistine.
General signiﬁcance: The peptides Paulistine and Acm-Paulistine may be used as interesting tools to investigate
the mechanisms of pain and inﬂammation in future studies.© 2013 Elsevier B.V. All rights reserved.1. Introduction
The venoms of the social Hymenoptera insects are used as part of
their chemical weaponry for defence and/or prevention against infec-
tion by pathogenic microorganisms; venom components may act as
toxins, hormones, antibiotics, and defensins, interacting with different
pharmacological targets and causing pain, inﬂammation, changes in
blood pressure, cardiac arrhythmia, and neurotoxicity amongst other
toxic effects [1–3].
Wasp venoms are composed of a complex mixture of free amino
acids, biogenic amines, and a series of polycationic peptides and proteins
[4]. The peptides represent approximately 70% of the dry weight of
venoms from social wasps [5]. Most of these peptides are linear,
polycationic and amphipathic molecules with a high α-helix content in
their secondary structures. These peptides generally cause cell lysis, he-
molysis, antibiosis, smooth muscle contraction, and chemotaxis.
Venom peptides may also promote the release of activators/mediators55 19 35348523.
ights reserved.from mast cells, leukocytes, and platelets through their interaction with
G-protein coupled receptors on the plasmamembranes of these cells [3].
Identiﬁcation of the peptides in venoms is important to characterise
the pharmacological symptoms observed during the envenoming pro-
cess. This knowledge will help physicians to assist the victims of sting-
ing incidents. The pharmacological properties of wasp venoms have
not yet been fully investigated because of the limited amount of
venom produced by wasps and the low abundance of each natural pep-
tide in these venoms.
The peptides from the venoms of social wasps are generally classi-
ﬁed into families according to the type of biological activities exhibited
by these peptides: i) mastoparans, which cause degranulation of
mast cells; ii) chemotactic peptides, which promote chemotaxis of
polymorphonucleated leukocytes [6]; iii) wasp kinins, which are
known to be pain-inducing peptides; and iv) very short peptides,
possessing a series of inﬂammatory activities [7].
A novel peptide named Paulistine with an unusual structure
amongst the peptide toxins from social wasps was isolated from the
venom of the wasp Polybia paulista, this peptide has 21 amino acid res-
idues in its sequence with a single intramolecular disulphide bridge.
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honeybee venom peptides, such as Apamine, Tertiapine, and MCD-
Peptide, which possess four cysteine residues forming two intramolec-
ular disulphide bridges [8]. A peptide similar to Paulistine named
Sylverine was previously reported by Dohtsu et al. (1993) [9] in the
venom from the neotropical social wasp Protonectarina sylveirae; how-
ever, the structure and biological activities of this peptide were never
investigated. Thus, the objective of thepresent studywas to characterise
the structure/function relationship of the novel wasp venom peptide
Paulistine, taking into account the importance of the oxidised and
reduced forms of the disulphide bridge for the maintenance of both
the molecular structure and the biological activities of this peptide.2. Material and methods
2.1. Biological material
The social wasp P. paulista was collected in Rio Claro, SP, southeast
Brazil (S22°23′49.7″; W047°32′54″), and immediately frozen and
stored at −20 °C. The venom reservoirs of 500 wasps (5 mg venom)
were removed with forceps and microscissors and suspended in 50%
(v/v) acetonitrile (MeCN). The reservoirs were then perforated with a
sharpmetallic stylet, and the venomwas extracted bywashing the bio-
logical material three times with the solvent. The suspension was then
centrifuged at 10,000 ×g for 10 min at 4 °C. The supernatants were
collected, pooled, lyophilised, and stored at−80 °C until use.2.2. Venom fractionation
The venomextract from P. paulistawas chromatographed in aCapcell
Pack C-18 UG120 column (10 mm × 250 mm, 5 μm, Shisheido) under a
linear gradient from 5 to 60% (v/v) MeCN/H2O [containing 0.1% (v/v)
triﬂuoroacetic acid (TFA)] at a ﬂow rate of 2.0 mL/min over 60 min
and monitored by UV absorption at 214 nm with a UV-DAD detector
(Shimadzu, mod. SPD-M10A). The fractions were manually collected in
glass vials and dried using a lyophiliser. Fraction 10 (containing both
the oxidised and reduced forms of Paulistine) was re-fractionated by
reverse-phase HPLC with a C-18 (ODS) Capcell Pack UG120 column
(10 mm × 250 mm, 5 μm, Shisheido) under an isocratic condition
with 40% (v/v) MeCN/H2O (containing 0.1%TFA) at a ﬂow rate of
2.0 mL/min over 20 min. The elution was monitored by measurement
of the UV absorption at UV 214 nm.2.3. Amino acid sequencing
The amino acids were sequenced using a gas phase sequencer PPSQ-
21A (Shimadzu) based on automated Edman degradation chemistry.2.4. Mass spectrometry
Mass spectrometric analysis was performed in an Ion Trap-Time
of Flight hybrid mass spectrometer (LCMS-IT-TOF) produced by
Shimadzu Co. The samples were injected into the LC–MS system
with an autosampler injector at a ﬂow rate of 0.2 mL/min of MeCN
50% (v/v). All analyses were performed in the positive electrospray
ionisation (ESI+) mode using typical conditions: CDL temperature of
200 °C, a capillary voltage of 4.5 kV, a cone voltage of 3.5 V, a ﬂow rate
of nebuliser gas (nitrogen) of approximately 1.5 L/h and a drying gas
(nitrogen) ﬂow rate of 100 L/h. The ESI mass spectra were obtained in
the continuous acquisition mode, scanning from m/z 50 to 4000 during
2 min. The data were acquired and analysed using LCMS solution soft-
ware (SHIMADZU).2.5. Peptide synthesis
The peptides were prepared by stepwise manual solid-phase
synthesis using N-9-ﬂuorophenylmethoxy-carbonyl (Fmoc) chemistry
withNovasyn TGS resin (NOVABIOCHEM). Side-chain protective groups
included trityl (Trt) for glutamine, t-butyl (tBu) for serine and threo-
nine, t-butoxycarbonyl (Boc) for lysine, and β-t-butyl ester (OtBu) for
aspartic acid. The side-chain protective group trityl (Trt) was used in
the synthesis of the oxidised peptide (with the disulphide bridge),
while acetamidemethyl (Acm) was used for blocking the free thiol
groups of the cysteine residues in the synthesis of the reduced peptide
with the thiol groups permanently blocked.
Cleavage of the peptide–resin complexes was performed by treat-
ment with triﬂuoroacetic acid/1,2-ethanedithiol/anisole/phenol/water
(82.5:2.5:5:5:5 by volume) at room temperature for 2 h. After ﬁltering
to remove the resin, anhydrous diethyl ether (Sigma) at 4 °C was
added to the soluble material to cause precipitation of the crude pep-
tide, which was collected as a pellet by centrifugation at 1000 ×g for
15 min at room temperature. The crude peptide was solubilised in
water and puriﬁed by RP-HPLC. The peptide with the disulphide bridge
was obtained by air oxidation of cysteine residues as described else-
where [10].
Synthetic Paulistine peptides (in oxidised form with a disulphide
bridge and in reduced and acetoamidated forms), were puriﬁed by
high performance liquid chromatography (HPLC, mod. LC 8A) using a
Shim-Pack C-18 Prep-ODS (K) column (30 mm x 250 mm, 15 μm,
Shimadzu) under isocratic elution with 45% (v/v) MeCN/H2O [contain-
ing 0.05% (v/v) TFA] at a ﬂow rate of 10 mL/min. The elution was mon-
itored at 214 nm with a UV–vis detector (Shimadzu, mod. SPD-20A
Prominence). The fractions were manually collected and dried using a
lyophiliser (Heto). The homogeneity and correctness of the sequence
of the synthetic peptides were assessed using a gas-phase sequencer
PPSQ-21A (Shimadzu) based on automated Edman degradation chem-
istry and ESI-MS analysis.
2.6. Circular dichroism measurements
To evaluate conformational changes in the peptides induced by dif-
ferent membrane-mimetic environments, CD spectra were obtained at
a peptide concentration of 20 μM in either bi-distilled water, 40% (v/v)
2,2,2-triﬂuoroethanol (TFE)/water, or sodium dodecyl sulphate solu-
tions (SDS) above and below the critical micelle concentration (CMC)
of SDS (8 mM and 165 μM SDS, respectively). CD spectra were
recorded from 260 to 190 nm with a Jasco-710 spectropolarimeter
(JASCO International Co. Ltd., Tokyo, Japan) calibrated routinely at
209 nm using a D-Pantolactone solution [11]. Spectra were acquired
at 25 °C using a 0.5 cm path length cell at a scan speed of 20 nm/min,
a bandwidth of 1.0 nm, a response of 0.5 s, and a resolution of 0.1 nm.
Eight scans were acquired for each spectrum. Following a baseline
correction, the observed ellipticity in θ (mdeg) was converted to
mean residue ellipticity [Θ] (deg cm2/dmol), using the relationship
[Θ] = 100 θ/(l c n) where “l” is the path length in centimetres, “c” is
the peptide millimolar concentration, and “n” is the number of peptidic
bonds. Assuming a two-state model, the observed mean residue ellip-
ticity at 222 nm (Θobs222) was converted into an α-helix fraction (fH)
using themethod proposed by Rohl and Baldwin (1998) [12] and previ-
ously described elsewhere [13].
2.7. Molecular modelling
The search for templates of the Paulistine sequence was performed
with the Blastp tool [14] and the alignment was formatted and input
into the programme. The structure of the homologous peptide, which
was experimentally solved by NMR (PDB ID: 2KGH) [15], was selected
from the Protein Data Bank (PDB) [16]. Synthetic peptide models were
built with restraint-based modelling implemented in MODELLER [17]
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by the satisfaction of spatial restrains [18,19]. For each peptide, a total
of 1000models were created and the best ones were selected according
to the MODELLER objective function [20] and stereochemical analysis
with PROCHECK [21]. The sequence similarity between Paulistine and
the template was 61% (identity 38%). The ﬁnal models were selected
with 100% of the residues in favoured regions of the Ramachandran
plot, with the best values of the overall G-factor and lower values of
energy minimisation. Both reduced and oxidised forms of Paulistine
were modelled; the reduced peptide was modelled considering the
acetamidemethylation of the thiol groups of cysteine. Pymol was used
for the visualisation of the models of both forms of Paulistine [22].
2.8. Molecular dynamics simulations
The MD simulations were performed with the GROMACS 4.5.5 soft-
ware package [23] using the GROMOS 96 force ﬁeld 43a2 [24] and the
ﬂexible SPC (Simple Point Charge) water mode [25]. For TFE molecules
in the simulation, the model and simulation conditions were applied as
proposed by Fioroni et al. (2001) [26]. Simulations of both peptides
were carried out in a cubic box containing TFE andwater corresponding
approximately to a mixture of 40:60% (v/v) TFE:water in which the
minimum distance between the peptide surface and the box face was
1.0 nm length in all directions and neutralised with ﬁve Cl− counter-
ions. During the simulations, bond lengths within the peptides were
constrained by the LINCS algorithm [27] and the SETTLE algorithm [28]
was used to constrain the water geometry. In the initial MD simulation
of both forms of Paulistine, all hydrogen atoms, ions, and water mole-
cules were subjected to 500 steps of energy minimisation by steepest
descent to remove close van der Waals contacts. Both systems were
then submitted to a short molecular dynamics simulation with position
restraints for a period of 2000 ps (ps). The ﬁnal MD simulations were
performed under the same conditions, except that the position
restraints were removed after an interval of 20,000 ps. Energy
minimisation and MD were carried out under periodic boundary
conditions. The simulation was computed in the NPT ensemble at
300 K with Berendsen temperature coupling and a constant pressure of
1 atm with isotropic molecule-based scaling [29,30]. Temperature and
pressure were modulated using coupling techniques [29] with coupling
and isothermal compressibility constants of 0.01 ps (solvent and pep-
tide) and 6.5 × 10−5 bar−1, respectively. The electrostatic interactions
between non-ligand atoms were evaluated by the particle mesh Ewald
method [31]. Cutoff distances for the calculation of the Coulomb and
van der Waals interactions were 1.0 and 1.4 nm, respectively. The con-
vergences of the different simulations were analysed in terms of the
radius of gyration (RG), root mean-square deviation (RMSD) from the
initial structures of the models, and types of intermolecular hydrogen
bonds. All analyses were performed on the ensemble of system conﬁgu-
rations extracted at 0.5 ps time intervals from the simulation and theMD
trajectory collection was initiated after 1 ns of dynamics to ensure a
completely equilibrated evolution. The molecular visualisation was
performed in the graphical environments VMD [32] and PyMOL [22].
2.9. Biological assays
2.9.1. Hemolytic activity
Washed rat red blood cells (WRRBC) were used to evaluate the
hemolytic activity of the peptides. WRRBC were prepared by washing
red blood cells of Wistar rats three times with physiological saline solu-
tion (NaCl 0.85% and CaCl2 10 mM). Aliquots ofWRRBCwere then incu-
bated at 25 °C in the presence of each peptide for 120 min with gentle
mixing. Samples were then centrifuged and the absorbances of the
supernatants were measured at 540 nm. The absorbance measured
from lysedWRRBC in the presence of 1% (v/v) Triton X-100was consid-
ered to be 100%.2.9.2. Mast cell degranulation activity
Mast cell degranulation activity was determined by measuring the
release of β-D-glucosaminidase [33]. Mast cells were incubated in the
presence of peptides for 15 min at 37 °C. After centrifugation, the super-
natants were sampled for use in the β-D-glucosaminidase assay for a
period of 6 h. After incubation, 50 μL of the supernatant solution was
added to 150 μL of 0.2 M Tris and the absorbance was measured at
405 nm. The values were expressed as the percentage of total β-D-
glucosaminidase activity from rat mast cell suspensions, relative to
lysed mast cells in the presence of 0.1% (v/v) Triton X-100 (considered
to be the 100% reference). The results were compared to the activities
measured for the standard mast cell degranulating peptide HR-II
(SIGMA).
2.9.3. Chemotaxis assays
Chemotaxis was assayed in a speciﬁc multi-chamber apparatus
(NEUROPROBE) by using polymorphonucleated leukocytes (PMNL)
obtained from subcutaneous inﬂammatory induction in Wistar rats as
proposed by Falk (1980) [34]. The upper chambers were ﬁlled with
200 μL of a PMNL suspension (5 × 105 cells/mL in a 0.9% NaCl solution)
and the lower chambers were ﬁlled with 400 μL of physiological saline
solution containing various concentrations of the peptides (10−7
to 10−4 M). A polycarbonate membrane containing pores of 10 μm
in diameter was placed between both chambers. The chemotaxis
chamber was incubated at 37 °C for 1 h. After incubation and violet
crystal staining, cells in the lower chamber were counted using a
Neübauer chamber under a microscope. The results are expressed
as the mean ± the S.D. of ﬁve experiments.
2.9.4. Antimicrobial activity
The minimal inhibitory concentrations (MIC) of the peptides were
determined based on the methods described in [35]. The following
microorganisms were used: Staphylococcus aureus (ATCC 6538),
Streptococcus pneumoniae (ATCC 11733), Bacillus cereus (ATCC
11778), Escherichia coli (ATCC 1175) and Pseudomonas aeruginosa
(ATCC 13388).
2.9.5. Hyperalgesic and edematogenic effects
Male Swiss mice, weighing between 25 and 30 g, were used
throughout this study. Mice were housed under controlled humidity
at a temperature of 22 °C ± 1 in a sound-attenuated room subject to
a 12 h light–dark cycle. Food and water were available ad libitum and
mice were taken to the testing room at least 1 h before the experiment.
All behavioural testing was performed between 9:00 am and 4:00 pm.
The mice were used only once. All experiments were in accordance
with the guidelines for the ethical use of conscious animals in pain
research, published by the International Association for the Study of
Pain [36] and EC Directive 86/609/EEC for Animal Experiments. The
procedures were approved by the Institutional Animal Care Committee
at Butantan Institute (CEUAIB, protocol no. 567/09).
2.9.5.1. von Frey electronic pressure-meter paw tests for mice. Mice were
placed in acrylic cages (12 × 10 × 17 cm high) with a wire grid ﬂoor
15–30 min before testing. During this adaptation period, the paws
were poked 2–3 times. Before paw stimulation, the animals were quiet,
without exploratory movements or defecation and not resting on their
paws. In these experiments, we used a pressure-meter, which consisted
of a hand-held force transducer ﬁtted with a 0.5 mm2 polypropylene tip
(electronic von Frey anesthesiometer, IITC Inc., Life Science Instruments,
WoodlandHills, CA, USA). The investigatorwas trained to apply the poly-
propylene tip perpendicularly to the central area of the hind paw with a
gradual increase in pressure. A tilted mirror below the grid provided a
clear view of the animal's hind paw. The test consisted of poking a hind
paw to provoke a ﬂexion reﬂex followed by a clear ﬂinch response
after pawwithdrawal. In the electronic pressure-meter test, the intensity
of the stimulus was automatically recorded when the paw was
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paw was repeated until the animal presented two similar measure-
ments. If the resultswere inconsistent (i.e., a great difference in the base-
line response compared to the other animals of the experiment was
observed), another animal was used. Hyperalgesic effect was induced
by the injection by the intraplantar (i.pl.) route of either carrageenin
(300 μg/50 μL) or peptides (10 and 30 μg/50 μL) into one of the hind
paws. The results are reported as the Δ (delta) withdrawal threshold
(g) which was calculated by subtracting the values obtained after the
treatments from the ﬁrst measurement (before treatment).
2.9.5.2. Evaluation of oedema. Oedema was induced by the injection of
carrageenin (300 μg/50 μL) or peptides (10 and 30 μg/50 μL) into one
of the hind paws by the intraplantar (i.pl.) route. The volume increase
(oedema) of paws up to the tibio-tarsal articulation was measured
using a digital paquimeter (Mitutoyo, CD-6 CSX-B model, Brazil).
Indomethacin and Zileuton were administrated to evaluate the
antiedematogenic effect. The difference between the values obtained
for both paws expressed as percent increase in paw volume was used
as a measure of oedema.
2.9.5.3. Evaluation of nociceptivity. For evaluation of the nociceptive
activity of Paulistine and Acm-Paulistine, both peptides were dissolved
in sterile saline (10 and 30 μg/50 μL) and administered by the i.pl.
route into one of the hind paws of the mice. A hypodermic 26-G needle
was inserted into the skin of the second footpad (to avoid back ﬂow)
and the tip of the needle was introduced until the central area of the
hind paw was in the same place where either the ﬁlaments or the tip
of the pressure meter were applied. The nociceptive activity was evalu-
ated at different times (before treatment and 30, 60, 120 and 300 min
after Paulistine and Acm-Paulistine application) and compared to the
control. Carrageenin (Marine Colloids, 300 μg/50 μL) was diluted in
sterile saline and used as positive control; sterile saline was used as a
negative control. To assess the involvement of arachidonatemetabolites
in this phenomenon, different groups of rats were treated with either
the cyclooxygenase inhibitor indomethacin (SIGMA, USA, 100 μg/25 μL
in 0.1 M Tris–HCl buffer at pH 8.0) (control) or with the type 2 cycloox-
ygenase inhibitor Celecoxib (30 mg/kg administered by an oral route)
30 or 120 min (respectively) before the injection of the peptides [37].
The lipoxygenase inhibitor Zileuton (Abbott Laboratories, Zyﬂo®, USA)
was diluted in an hydroalcoholic solution (10% ethanol) and assayed
60 min before injection of the peptides (100 mg/kg administered by
an oral route) [38]. To evaluate the involvementof leukotriene receptors,
Zaﬁrlukast (SIGMA, USA)was diluted in 0.5% dimethyl sulfoxide (DMSO,
SIGMA, USA) and administered by an oral route at 5.0 mg/kg. Animals
injected with hydroalcoholic solution plus sterile saline was used as a
control group.Fig. 1. A) Chromatographic fractionation of venom extract from Polybia paulista by RP-HPLC un
2.0 mL/min over 60 minwith UVmonitoring at 214 nm. B) Re-chromatography of fraction 10 b
the mobile phase with a ﬂow rate of 2.0 mL/min over 20 min with UV monitoring at 214 nm.2.10. Statistical analysis
Two-way analysis variance (ANOVA) was used to compare the
groups and doses over all times. Three factors were analysed: treat-
ments, time and time vs. treatment interaction. When a signiﬁcant
time vs. treatment interaction was detected, one-way ANOVA followed
by the Tukey test was performed for each time point to distinguish dose
effects. One-way ANOVA followed by the Tukey test was also used for
dose–response curves for a single time point. The results with p b 0.05
were considered to be signiﬁcant [39].
3. Results
3.1. Structural characterisation
A P. paulista venomextract (5 mg) containing approximately 3.5 mg
of peptideswas fractionated by reverse-phaseHPLC resulting in the elu-
tion of thirteen fractions (designated 1 to 13 in Fig. 1A). Fractions 1 to 3
consisted of free amino acids and biogenic amines; fraction 4 was
characterised as serotonin; fractions 5 to 9 were determined to be
very low abundant venom components not previously characterised;
and fractions 11 to 13 consisted of mastoparan peptides that have
been biochemically and functionally characterised in previous publica-
tions [40,41]. The Paulistine peptide was identiﬁed in fraction 10
(Fig. 1A), which was then re-fractionated, resulting in the elution of
four other peaks (designated as 10.1 to 10.4). Paulistine eluted at fraction
10.2 (Fig. 1B); the ESI/MS spectrum of this fraction is shown in Fig. 2A,
where is possible to observe the peaks of m/z values 472.87, 590.83,
and 787.44, corresponding to the molecular ions as [M + 5H]+5,
[M + 4H]+4, and [M + 3H]+3, respectively (Fig. 2A); the deconvolution
of this spectrum revealed that the peptide present in this fraction
presented amolecular mass of 2359.32 Da. Thus, the mass spectrometric
analysis indicated that the peptide was pure enough to be sequenced
through automated Edman degradation chemistry, which revealed the
sequence SIKDKICKIIQAQCGKKLPFT-NH2. This novel peptide from social
wasp venom was named Paulistine.
The sequence of Paulistine determined by Edman degradation ap-
parently possesses two cysteine residues at positions 7 and 14; thus,
the connectivity between these residues was checked by ESI-IT-TOF-
MS analysis. The peptide treated with dithiothreitol indicated a molec-
ular mass of 2361.32 Da (results not shown), suggesting that both cys-
teine residues are connected to each other to form an intramolecular
disulphide bridge (Fig. 3).
The ESI-IT-TOF-MS analysis of fraction 10.3 revealed the peaks of
m/z 591.31, 788.08, and 1181.62, corresponding to the molecular ions
as [M + 4H]+4, [M + 3H]+3, and [M + 2H]+2, respectively (Fig. 2B);
the deconvolution of this spectrum revealed that the peptide presentder a linear gradient from 5 to 60% (v/v)MeCN/H2O (containing 0.1% TFA) at a ﬂow rate of
y RP-HPLC under an isocratic condition using 40% (v/v)MeCN/H2O (containing 0.1%TFA) as
Fig. 2.MS1 spectra, in the positive mode, of: (A) naturally oxidised Paulistine peptide present in fraction 10.2, showing the peaks of m/z 472.87, 590.83, and 787.44, corresponding to the
molecular ions as [M + 5H]+5, [M + 4H]+4, and [M + 3H]+3, respectively; (B) naturally reduced peptide present in fraction 10.3, showing the peaks ofm/z 591.31, 788.08, and 1181.62,
corresponding to themolecular ions as [M + 4H]+4, [M + 3H]+3, and [M + 2H]+2, respectively; (C) reduced and acetamidemethylatedpeptide,where is possible to observe thepeaks of
m/z 501.61, 626.86, and 835.48, corresponding to the molecular ions as [M + 5H]+5, [M + 4H]+4, and [M + 3H]+3, respectively.
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was also sequenced by Edman degradation chemistry and was found to
correspond to the naturally occurring reduced form of Paulistine. The
naturally oxidised peptide (fraction 10.2) is relatively stable, i.e., it is
slowly converted to its reduced form, even under rest at 4 °C and
protected from the light. However, the puriﬁed peptide from fractionFig. 3. Sequences of oxidised and reduced + acetamidemethylated Paulistine.10.3 (naturally reduced) quickly oxidises spontaneously until achieve
an equilibrium in a proportion of 1:4 (reduced: oxidised).
Because the amount of natural peptides recovered from the puriﬁca-
tion protocol was strongly biased by the detection of the reduced form
(65 μg of the reduced peptide was recovered from fraction 10.3 com-
pared to 280 μg of the oxidised peptide from fraction 10.2), Paulistine
was chemically synthesised in its oxidised and reduced forms, as well
as a reduced form in which the thiol groups from the cysteine residues
were coupled to an acetamidemethyl moiety (Fig. 3). Peptides were
manually synthesised in the solid-phase using an Fmoc strategy.
Oxidised Paulistine was obtained by air oxidation after its cleavage
from the resin. Synthetic peptides were individually puriﬁed by RP-
HPLC (C18) using isocratic elution with 40% (v/v) MeCN containing
0.1% TFA. Oxidised Paulistine eluted at 9.75 min, while the reduced
and acetamidemethylated forms (Acm-Paulistine) eluted at 9.20 min
(Fig. 4). The accuracy of the sequences of the synthetic peptides was
Fig. 4. Chromatographic proﬁles of the fractionation of synthetic oxidised ( ) and reduced + acetamidemethylated Paulistine under RP-HPLC (LC-8A) (- - - -) with a C-18 ODS-K Shim-
Pack column (250 mm × 30 mm, 15 μm) under isocratic elutionwith 40% (v/v)MeCN (containing 0.1%TFA) as themobile phase at a ﬂow rate of 20.0 mL/min over 25 minwith UVmon-
itoring at 214 nm.
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geneity of the preparation was checked by ESI-IT-TOF-MS analysis;
Fig. 2C shows the ESI/MS spectrum of the acetamidemethylated pep-
tide, where it is possible to observe the peaks of m/z 501.61, 626.86,
and 835.48, corresponding to the molecular ions as [M + 5H]+5,
[M + 4H]+4, and [M + 3H]+3, respectively. The deconvolution of this
spectrum revealed a molecular mass of 2503.44 Da. Themass difference
of 144 Da between the oxidised and the chemicallymodiﬁed formof the
peptide corresponds to the introduction of the two acetamidemethyl
groups into the peptide (2 × 72 Da = 144 Da). This strategy ensures
that the reduced peptide will not oxidise the thiol groups to reform
the disulphide bridges.
Considering the importance of secondary structure for understanding
thebiological activities of peptides, the secondary structures of Paulistine
and Acm-Paulistine were investigated by CD spectroscopy. The CD spec-
tra of the oxidised and reduced forms of Paulistine in water, 40% (v/v)
TFE, and in the presence of SDS above and below the CMC of SDS (atFig. 5. CD spectra of (A) Paulistine and (B) Acm-Paulistine at 20 μM concentration acquired fro
SDS.165 μM and 8 mM SDS, respectively) are shown in Fig. 5A. The corre-
sponding spectra of Acm-Paulistine are shown in Fig. 5B.
Table 1 presents the molar ellipticity ([Θ222]) and the α-helix frac-
tions (fH*) in the different environments. Theα-helix fractionswere cal-
culated according to the two-state model [12], while the fractions of
secondary structure were obtained by ﬁtting the spectra with the
CONTIN and SMP56 programmes within CDPro. It was found that the
oxidised peptide possesses a lower helical content and higher strand
content than the reduced and acetamidemethylated peptides.
Themolecularmodels of Paulistine and Acm-Paulistine are shown in
Fig. 6A and B, respectively. The analysis of the Ramachandran plot for
these molecular models (supplementary information) revealed that
76.5% of the residues lie in the most favourable regions and 23.5% in
the additionally allowed regions for the oxidised form of Paulistine.
Meanwhile, the same analysis for the Acm-Paulistine model reveals
that 76.5% of the residues lie in the most favourable regions, 17.6% in
the additional allowed regions and 5.9% in generously allowed regions.m260 to 190 nm at 25 °C in the presence of water, 40% (v/v) TFE, 165 μM SDS and 8 mM
Table 1
Secondary structure evaluation of Paulistine andAcm-Paulistine indifferent environments:water, 40% (v/v) TFE solution, 165 μMSDS, and 8 mMSDSmolar ellipticity ([Θ]222) andα-helix
fractions (fH*) were calculated according to the two-state model [12], and the fraction content of helical (H), strand (S) and unordered (Unrd) structures was obtained from the ﬁtting of
spectra with the programme CDPro (CONTIN, SMP56).
Paulistine Acm-Paulistine
[Θ]222 fH⁎ H S Unrd [Θ]222 fH⁎ H S Unrd
Water −1324 ± 46 rc – – – −1328 ± 46 rc – – –
40% TFE −5088 ± 103 0,17 0.20 0.27 0.30 −8714 ± 121 0,30 0.35 0.15 0.29
165 μM SDS −403 ± 187 – 0.05 0.45 0.28 −6412 ± 35 0,22 0.26 0.23 0.30
8 mM SDS −4044 ± 66 0,13 0.19 0.28 0.30 −7206 ± 71 0,25 0.31 0.20 0.28
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ies. The molecular model of Paulistine possesses a small helix that is
maintained and most likely stabilised by the disulphide bridge
(Fig. 6A). The model of Paulistine is therefore more compact than the
model of Acm-Paulistine, which possesses a more extended conforma-
tion (Fig. 6B) presumably due to the reduction of the thiol groups.
Despite the fact that these molecular models were considered
adequate by the criteria considered above, they are staticmodels. To ob-
tain a more realistic idea about the structures of these peptides, the ini-
tial models were submitted to molecular dynamics analysis. The
simulations were carried out both for oxidised and reduced forms of
the peptide (Paulistine and Acm-Paulistine, respectively). The purpose
of performing molecular dynamics was to investigate the stability of
the secondary structure of the peptide with and without the cysteine
bridge. This was performed by evaluating different variables:
i) The root-mean square deviation (RMSD) of the positions for all
backbone C-α atoms as a function of simulation time (Fig. 7A).
The analysis of the RMSD indicates that the reduced and
acetoamidated forms of Paulistine show higher RMSD values
when compared to oxidised Paulistine. The RMSD values for the
C-α atoms of Acm-Paulistine rapidly increased initially during
the MD simulation. However, this was followed by a period of
relative stability for most of the remaining time of the MD simu-
lation. The RMSD values for the C-α atoms of Paulistine remained
stable throughout the MD simulation, suggesting that 20 ns of
unrestrained simulation was sufﬁcient to stabilise both peptides.
ii) The radius of gyration is the root mean square distance of the
atoms in relation to the axes x, y and z of a speciﬁc molecule,
and it can give an idea about the size and compactness of a mol-
ecule. In Fig. 7B it can be seen that the reduced peptide has a
radius of gyration of 1.700 nm after 20 ns simulation, while the
corresponding value for the oxidised form of the peptide was
0.800 nm after 4 ns simulation, which remained stable until
20 ns into the simulation. These results indicate that theFig. 6.Molecular models of A) Paupresence of the disulphide bridge stabilises the peptide into a
more compact molecular structure. The continuing increase in
the radius of gyration during the simulation for the reduced pep-
tide indicates that the absence of the disulphide bridge makes
the structure of this peptide less stable and more expanded
than that of the oxidised peptide.
iii) Analysis of the potential energy (Fig. 7C) shows that the peptides
reached equilibriumanddonot exhibit any asymptotic behaviour.
iv) The analysis of the prevalence of hydrogen bonds during the MD
simulation shows that the number of hydrogen bonds in the
oxidised peptide increased from 22 to 41 (with a rate value of
33), while in the reduced peptide the number of hydrogen
bonds increased from 33 to 58 (with a rate value of 47). Despite
this difference, the number of hydrogen bonds was relatively sta-
ble in both forms of the peptide during the simulation (Fig. 7D).
The surface charge representation of Acm-Paulistine (Fig. 8A) shows
three regions of positive residues alternated with regions of negative
residues in both faces of the molecule. It is easy to identify the
acetamidemethylated thiol groups in this representation (Fig. 8A). The
oxidised peptide (Paulistine) has a compact amphipathic structure
with one face of the molecule presenting only positive residues, while
the other face presents positive residues in two opposite borders with
negative residues in the other borders and centre (Fig. 8B).
3.2. Biological characterization
The biological characterisation of Paulistine and Acm-Paulistine was
evaluated by submitting these peptides to a series of activity assays to
examine hemolysis, mast cell degranulation, chemotaxis of PMNLs,
antibiosis, nociceptivity and edematogenic effect. Peptide stocks were
maintained under lyophilized form; fresh solutions of each peptide
form were prepared and immediately used to avoid to the conversion
oxidised to reduced forms. Neither peptide caused hemolysis, mast cell
degranulation or antibiosis (results not shown). However, chemotaxislistine and B) Acm-Paulistine.
Fig. 7.Molecular dynamics simulations of Paulistine and Acm-Paulistine: A) rootmean-square deviation (RMSD); B) radius of gyration (Rg); C) potential energy; and D) hydrogen bonds.
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of chemotactic activity were observed with each peptide. Paulistine and
Acm-Paulistine attracted 4.0 × 105 cells/mL and 1.8 × 105 cells/mL,
respectively, at a concentration of 1 × 10−5 M (Fig. 9).
3.2.1. Hyperalgesic and edematogenic effects
The injection of 10 and 30 μg Paulistine (Fig. 10A) and Acm-Paulistine
(Fig. 10C) caused a signiﬁcant increase of nociception, characterised by
hyperalgesia for both forms of Paulistine. The most intense effects for
30 μg Paulistine were observed between 30 and 120 min after peptide
administration, while for Acm-Paulistine more intense effects wereFig. 8. Structural models of Acm-Paulistine (A) and Paulistine (B) as charge surface representa
residues in blue.observed between 30 and 60 min. These phenomena disappeared
within 300 min for Paulistine (Fig. 10A) and within 120 min for
Acm-Paulistine (Fig. 10C). In both experiments carrageenin (Cg, i.pl.,
300 μg) was used as a standard compound for positive nociception,
while sterile saline was injected as control.
The injection of 10 and 30 μg of either Paulistine or Acm-Paulistine
induced an increase in paw volume (Fig. 10B and D, respectively). The
edematogenic effect of Paulistine was initiated after 30 min of its appli-
cation in rats, while for Acm-Paulistine these effects were observed
immediately after its application. It is important to note that the
edematogenic effect caused by the injection of 30 μg Paulistinetions in two different molecular surfaces. Negative residues are shown in red and positive
Fig. 9.Chemotaxis of PMNL cells for the peptides Paulistine andAcm-Paulistine at different
concentrations. The values represent the mean ± S.D. (n = 5).
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carrageenin (the positive control); these phenomena disappeared in
300 min after the start of application for Paulistine and after 120 min
for Acm-Paulistine.
3.2.2. Involvement of eicosanoids on hyperalgesic and edematogenic effects
Because both forms of the peptide induced hyperalgesia and edema
effects, the next objectivewas to evaluate the involvement of prostanoids
and lipid mediators derived from the cyclooxygenase and lipoxygenase
pathways in the effects mentioned above. Mice were treated with either
indomethacin (I, 100 mg i.pl.) — a cyclooxygenase pathway inhibitor or
Zileuton (Z, 100 mg/kg taken by oral route in 500 μL) — a lipoxygenase
pathway inhibitor, before the injection of Paulistine (30 μg i.pl.) and
mechanical hyperalgesia was evaluated using an electronic von FreyFig. 10. Evaluation of the hyperalgesic and edematogenic effects of Paulistine and Acm-Paulist
induce paw withdrawal was recorded as the pain threshold represented by delta (Δ) (A and C
data were obtained at time 0 and at 30, 60, 120 and 300 min after Paulistine (A and B), Acm-
The control group were animals injected with sterile saline (S). The results are expressed as t
values of the saline (S) group; #p b 0.001 signiﬁcant difference from the mean values of the cainstrument and edema formation was monitored using measurements
with a digital paquimeter. The results shown in Fig. 11A revealed that
Zileuton inhibited the hyperalgesia induced by Paulistine when com-
pared with the control group (Paulistine/saline). On the other hand, in-
domethacin did not inhibit this phenomenon (I + Paulistine). Both
Zileuton and indomethacin inhibited the edema induced by Paulistine
compared to the control group (Fig. 11B). It is important to note that
the effect of Zileuton was more prominent than indomethacin.
None of the drugs altered the pain threshold per se or edema in the
animals treated (data not shown). The additional control groups
consisted of animals treated with saline/Tris, saline/indomethacin, and
saline/water/alcohol. These treatments did not interfere with the
hyperalgesic and edematogenic effects in animals during the observa-
tion period (data not shown).
In a similar experiment described above, the results showed that
indomethacin inhibited the hyperalgesia induced by Acm-Paulistine,
while Zileuton did not inhibit this phenomenon (Fig. 12A). However,
Zileuton and indomethacin both inhibited the edema induced by
Acm-Paulistine (Fig. 12B). It is important to note that the effect of indo-
methacin was more prominent for Acm-Paulistine than for Paulistine.
3.2.3. Involvement of leukotriene receptors in the hyperalgesic and
edematogenic effects of Paulistine
Because the results presented herein showed that Zileuton inhibited
the hyperalgesia and edema induced by Paulistine, we decided to inves-
tigate the involvement of leukotriene receptors in these mechanisms.
For this purpose, Zaﬁrlukast (ZF), a leukotriene receptor antagonist
[42], was injected (5 mg/kg in 300 μL of a DMSO 0.5% — vehicle
taken by an oral route) prior to Paulistine injection (assigned as
[ZF + Paulistine] in Fig. 13).ine. Paw threshold was estimated by the electronic von Frey device. The force needed to
). Edematogenic effects were evaluated using a digital caliper paquimeter (B and D). The
Paulistine (C and D) (10 and 30 μg i.pl.), or carrageenin (Cg, 300 μg i.pl.) administration.
he mean ± SEM of 5 animals per group. *p b 0.001 signiﬁcant difference from the mean
rrageenin (Cg) group.
Fig. 11. Involvement of eicosanoids on the hyperalgesic and edematogenic effects of
Paulistine. The paw threshold was estimated in the electronic von Frey device. The force
needed to induce paw withdrawal was recorded as the pain threshold represented by
delta (Δ) (A). Edematogenic effects were evaluated using a digital paquimeter (B). The
datawere obtained at time 0 and 60 min after Paulistine (30 μg i.pl.) administration. Indo-
methacin (I, 100 μg i.pl.) and Zileuton (Z, 100 mg/kg, by oral route in 500 μL)were admin-
istered at 30 min and 1 h before peptide injection, respectively. The control group were
animals injected with [Paulistine/saline]. The results are expressed as the mean ± SEM
of ﬁve animals per group. *p b 0.001 signiﬁcant difference from the mean values of
[Paulistine/saline].
Fig. 12. Involvement of eicosanoids in the hyperalgesic and edematogenic effects of Acm-
Paulistine. The paw threshold was estimated in the electronic von Frey device. The force
needed to induce paw withdrawal was recorded as the pain threshold represented by
delta (Δ) (A). Edematogenic effects were evaluated using a digital paquimeter (B). The
datawere obtained at time 0 and 60 min after Acm-Paulistine (30 μg, i.pl.) administration.
Indomethacin (I, 100 μg, i.pl.) [I + Acm-Paulistine] and Zileuton (Z, 100 mg/kg, by oral
route in 500 μL) [Z + Acm-Paulistine]were administered at 30 min and 1 h, respectively,
before peptide. The control group were animals injected with saline + Acm-Paulistine.
The results are expressed as themean ± SEM of ﬁve animals per group. *p b 0.001 signif-
icant difference from the mean values of [Acm-Paulistine/saline].
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hypernociceptive effect of Paulistine when compared to the group that
received Paulistine/saline; the group treated with a 0.5% (v/v)
Paulistine/DMSO showed no difference from the group that received
Paulistine/saline. Zaﬁrlukast did induce a signiﬁcant blocking of edema
induced by Paulistine (Fig. 13B). The group treated with a 0.5% DMSO
vehicle [Paulistine/DMSO] showed no difference from the control
group ([Paulistine/saline]).3.2.4. Effect of Celecoxib on hyperalgesia and edema induced by Acm-
Paulistine
Taking into account that Acm-Paulistine induced a hyperalgesic
effect in which prostaglandins are important mediators and the fact
that the cyclooxygenase inhibitor indomethacin inhibited this phenom-
enon, the next objective was to assess whether the generation of
prostanoids is dependent on the activity of the enzyme cyclooxygenase
type II. For this purpose, mice were previously treated with Celecoxib
(C, 30 mg/kg, administered by oral route), a selective inhibitor of the
enzyme cyclooxygenase type II, before injection of the Acm-Paulistine
(P, 30 μg, i.pl.) and then evaluated on the mechanical hyperalgesia test
[C + Acm-Paulistine]. The results shown in Fig. 14A reveal that
Celecoxib inhibited the hyperalgesia induced by Acm-Paulistine when
compared to the control group which received Acm-Paulistine/saline.
Another objective of this investigation was to evaluate the involvement
of cyclooxygenase type II on the edematogenic effect of Acm-Paulistine.
The results shown in Fig. 14B indicate that Celecoxib caused a decrease
in paw volume of animals when compared to the control group.4. Discussion
Amongst the venomsof socialHymenoptera insects, thepolycationic
peptides generally represent themost abundant types of peptide toxins,
which are represented bymast cell degranulators, hemolysins, antibiot-
ic components and chemotactic agents. While in honeybee venoms the
occurrence of peptides with disulphide bridges, such as Apamine,
Tertiapine, and MCD-Peptide, is relatively common [43], in social wasp
venoms there is a single report of a peptide containing a disulphide
bridge, the toxin Sylverin, which was poorly characterised structurally
and functionally [9].
A previous study also reported the presence of Paulistine occurring
naturally both in oxidised and reduced forms in the venom of the neo-
tropical socialwasp P. paulista [3]. Thus, this study presents the structur-
al characterization of Paulistine in its synthetic form, both with the
disulphide bridge (oxidised) and in its reduced form (i.e., without the
disulphide bridge, which was blocked by acetamidemethylation of the
thiol groups) to prevent the re-oxidation and formation of the Cys–
Cys disulphide bridge. The present manuscript focuses on the impor-
tance of the disulphide bridge for themolecular structure and biological
activity of Paulistine.
The secondary structures of Paulistine and Acm-Paulistine were
investigated by CD spectroscopy; spectra of both of these peptides in
water (Fig. 5A and B, respectively) are characteristic of unordered con-
formations. In a medium composed of 40% (v/v) TFE and also in 8 mM
SDS, the presence of two negative dichroic bands was observed, which
is consistent with the induction of α-helix conformations in these
Fig. 13. Involvement of leukotriene receptors in hyperalgesia and edema induced by
Paulistine. The paw threshold was estimated in the electronic von Frey device. The force
needed to induce paw withdrawal was recorded as the pain threshold represented by
delta (Δ) (A). The edematogenic effect was evaluated using a digital paquimeter (B).
Data were obtained at time 0 and 60 min after Paulistine (P, 30 μg, i.pl.) administration.
Zaﬁrlukast (ZF, 5 mg/kg, by oral route), an antagonist of the leukotriene receptor, was
administered before Paulistine administration [ZF + Paulistine]. The reference groups
were animals injected with [Paulistine/saline] and [Paulistine/DMSO]. The results were
expressed as themean ± SEM of ﬁve animals per group. *p b 0.001 signiﬁcant difference
from the mean values of [Paulistine/saline] and [Paulistine/DMSO].
Fig. 14. Effect of Celecoxib on hyperalgesia and edema induced by Acm-Paulistine. The
paw thresholdwas estimated in the electronic von Freydevice. The force needed to induce
paw withdrawal was recorded as the pain threshold represented by delta (Δ) (A). The
edematogenic effect was evaluated using a digital paquimeter (B). The datawere obtained
at time 0 and 60 min after Acm-Paulistine (P-Acm, 30 μg, i.pl.) administration. Celecoxib
(C, 30 mg/kg, by oral route), a selective inhibitor of enzyme cyclooxygenase type II, was
administered 120 min before Acm-Paulistine administration [C + Acm-Paulistine]. The
reference group were animals injected with Acm-Paulistine/saline, and the control
group were animals injected with saline alone [S]. The results were expressed as the
mean ± SEM of ﬁve animals per group. *p b 0.001 signiﬁcant difference from the mean
values of [Acm-Paulistine/saline], and [S].
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a slight deviation (207 and 223 nm) from the characteristic values usu-
ally obtained for an α-helix of 208 and 222 nm, which were observed
for Acm-Paulistine. SDS below the CMC tends to induce β-sheet confor-
mations and mimics the core environment of proteins [44]. Sequences
with either lower helical propensities or which show a tendency to
form aggregates will deviate from the helical pattern. The CD spectra
obtained in this environment clearly differentiate these peptides:
Acm-Paulistine shows the characteristic helical proﬁle, while Paulistine
presents lower helical content than its analog in anisotropic and
membrane-mimetic environments.
Table 1 presents the molar ellipticity ([Θ222]) and the α-helix frac-
tion (fH*) calculated according to the two-state model [12], in addition
to the data obtained by the ﬁtting of the spectra with CDPro (CONTIN,
SMP56) programmes in the different environments. The data obtained
with the help of CDPro programmes shows slightly higher helical con-
tents (regular and distorted α-helical content) than the analysis made
according to the two-state model for both peptides. This analysis also
shows that Paulistine possesses a higher content of strand structures
than Acm-Paulistine. Both peptides possess roughly the same amount
of unordered and turn structures (22%; data not shown in Table 1).
The analysis of the Ramachandran plot for each peptide (shown in
the Supplementary Results) reveals that both molecular models are
structurally reliable (Fig. 6A and B). Considering that the molecular
models created are generally static ones, a molecular dynamics (MD)analysis of the models generated for Paulistine and Acm-Paulistine
was performed to investigate the stability of the peptide with andwith-
out a disulphide bridge. To monitor the progress of conformational
changes of the peptides and to check the stability of its secondary struc-
ture elements during the simulation, the root-mean square deviation
(RMSD) of the positions for all theα-carbons of each peptide backbone
was evaluated as a function of simulation time. Analysis of the RMSD
indicates that Acm-Paulistine possesses RMSD values higher than
those observed for Paulistine over the entire 20 ns of simulation
(Fig. 7A). Accordingly, the Paulistine structure appears to bemore com-
pact and stable than the structure of Acm-Paulistine as shown in Fig. 7B,
which suggests that the disulphide bridge gives stability to the peptide.
Analysis of the potential energy of both molecules (Fig. 7C) shows that
both peptides reached equilibrium and did not exhibit any asymptotic
behaviour. The analysis of the prevalence of hydrogen bonds during
the MD simulation shows that the rate number of hydrogen bonds for
Paulistine is smaller than the rate number determined for Acm-
Paulistine; despite this difference the number of hydrogen bonds is rel-
atively constant for both peptides all over the simulation, indicating the
stability of the models (Fig. 7D).
When the molecular models of both forms of Paulistine were repre-
sented in the charge surfacemode it becomes clear that themolecules of
both peptides present two well distinguishable surfaces (Fig. 8A and B).
Biological assays showed that neither peptides induced hemolysis,
mast cell degranulation, or even antimicrobial activity, but both peptides
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the oxidised and reduced forms of Paulistine in the inﬂammatory
processes.
Pain inducedbyHymenoptera venomsmaybe intense, lasting for sev-
eral hours and burning for a few days [45]. Considering the algogenic and
inﬂammatory role played by wasp venom toxins, Paulistine and Acm-
Paulistine were submitted to assays of hyperalgesia and edematogenesis.
The assay of hyperalgesia demonstrated that Paulistine and Acm-
Paulistine induced pain at the same intensity, but at different times
after their administration to the model animals. The hyperalgesia caused
by Acm-Paulistine achieved its maximum activity 60 min after injection,
while for Paulistine this maximum was observed 120 min after peptide
administration (Fig. 10A to D). Thus, the hyperalgesia caused by Acm-
Paulistine is faster than the action of the oxidised peptide. A similar effect
was also reported for the edematogenic actions of Paulistine and Acm-
Paulistine, i.e., both forms of the peptide presented the same intensity
of edema formation; however, the action of Acm-Paulistine is faster, but
short-lasting than that caused by Paulistine.
It is important to note that Zileuton (a lipooxygenase inhibitor)
inhibited the hyperalgesia induced by Paulistine, but indomethacin
did not, suggesting that some type of lipid mediator is involved in the
phenomenon of hyperalgesia induced by Paulistine (Fig. 11A and B).
The opposite occurred for Acm-Paulistine (Fig. 12A and B). Thus, the
next objective was to assess whether this effect was mediated by a leu-
kotriene receptor. The use of the compound Zaﬁrlukast inhibited the
hyperalgesia caused by Paulistine, demonstrating the involvement of
leukotriene receptors in this activity (Fig. 13A and B).
In parallel, the investigation of the hypernociceptive effect of Acm-
Paulistine demonstrated that this effect most likely occurs throughFig. 15. A simpliﬁed scheme summarising the mechanisms involved in the nociceptive effect o
arachidonic acidmetabolism. Blue pathway and arrow— the cyclooxygenase pathwaymediates
way and arrow — the lipoxygenase pathway mediates the nociceptive mechanisms involved i
hydroxyeicosatetraenoic acid; 5-HETE: 5-hydroxyeicosatetraenoic acid; TXA2: thromboxanes;
LTB4 and LTA4: leukotrienes.interaction with the cyclooxygenase type II pathway, with the possi-
ble participation of prostanoids because Celecoxib counteracted the
hyperalgesia caused by the reduced/acetamidemethylated peptide
(Fig. 14A and B).
These data taken together suggest that distinctmechanismsmediate
the nociceptive effects observed for Paulistine and Acm-Paulistine; ap-
parently, both prostanoids and the lipid mediators seem to be involved
with the nociceptive effects observed for these peptides. Prostaglandins
(PGs) intensify the effect of pain indirectly through the actions of other
agents, such as 5-hydroxytryptamine or bradykinin. The PGs of -E and -F
series are released in inﬂammation, as well during tissue ischemia [46].
The lipoxygenase route results in the leukotriene formation, includ-
ing leukotriene B4 (LTB4), eicosatetranoic acid 5-oxo-6E, 8Z, 11Z, 14Z
and cysteinyl leukotrienes (LTC4, LTD4, LTF4 and LTE4), as well in the
activation of four leukotriene receptors (BLT1, BLT2, cysLT1 and
cysLT2). Leukotrienes are produced bymany inﬂammatory cells, partic-
ularly mast cells, basophils, eosinophils, neutrophils and macrophages
[46]. Zileuton, is the only drug commercially available as inhibitor of
5-lipoxygenase pathway; it blocks the production of LTB4 [46]. The bio-
logical actions of cysteinyl leukotrienes aremediated by the stimulation
of CysLT1-receptors, which is competitively inhibited by Zaﬁrlukast.
Thus, while Zileuton inhibits the leukotriene synthesis, Zaﬁrlukast
blocks the leukotriene receptors [47].
Moreover, both Zileuton and indomethacin inhibited the edema
caused by Paulistine and Acm-Paulistine, respectively, suggesting that
both prostanoids and lipid mediators mediate this phenomenon. The
results of the present study show that, with regard to the edematogenic
effect, the most prominent inhibition was caused by Zileuton with
Paulistine and indomethacin with Acm-Paulistine.f Paulistine and Acm-Paulistine on the generation of prostanoids and other eicosanoids by
the nociceptivemechanisms involved inmediating the effect of Acm-Paulistine; red path-
n mediating the effect of Paulistine. HETEs: hydroxyeicosatetraenoic acids; 12-HETE: 12-
PGF2, PGD2, PGE2 and PGI2: prostanoids; PAF: platelet-activating factor; LTE4, LTD4, LTC4,
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no direct relationship between the development of hyperalgesia and
edema caused by Paulistine and Acm-Paulistine. The mechanisms in-
volved in these effects are different fromeach other, showing the involve-
ment of prostanoids in the hyperalgesic process or the involvement of
lipid mediators in the edematogenic effects (or vice-versa).
The inﬂammatory process is often associated with hyperalgesia and
pain. Hyperalgesia can be deﬁned as a pathophysiological manifestation
resulting from sensitization of nociceptors and is a key event in the
development of inﬂammatory pain. The hypersensitive inﬂammatory
pain is the result of alterations in signal transduction in peripheral ter-
minals (nociceptors) of high activation threshold and in excitability in
the central nervous system [48].
Moreover, it was also reported divergence between the development
of hyperalgesia and edema, induced by the venom of Phoneutria
nigriventer [49]; this venom contains histamine and serotonin which
could interfere with sensorial neuroactivities, and therefore could con-
tributewith for its algogenic effect [50]. It was also reported that different
mechanisms are involved in the development of hyperalgesia and edema
inducedby the venomofBothrops asper, inwhichhyperalgesiawas quick-
ly controlled by drugs endowed with anti-inﬂammatory activity [51].
It is important to consider that chemical blockage caused by the
acetamidemethylation of the thiol groups of cysteine residues caused
small structural changes, which in turnmay have affected some physico-
chemical properties of the Paulistine. Thus, the presence of two free thiol
groups in the peptide would allow dipole–dipole interaction with the
speciﬁc receptor of the reduced form of Paulistine. The insertion of
Acm-group at this position to block the oxidation of thiol groups certainly
affected the native structure and its possible interaction with the speciﬁc
receptor, and consequently the proﬁle of the biological activities of Acm-
Paulistine. Thus, the dissociation of the hyperalgesy from the
edematogenic effect when the actions of Paulistine and Acm-Paulistine
are compared to each other,may be resulting from the inﬂuence of the in-
troduction of Acm-group in the proﬁle of structure–activity of Paulistine.
5. Conclusion
The results of the present investigation revealed an interesting ex-
ample of two different conformations of the same peptide (Paulistine)
coexisting at equilibrium in wasp venom, based on the maintenance
of a balance between the oxidised and reduced forms of the thiol groups
from the two cysteine residues in the peptide sequence.
Thus, the results of the present investigation suggest that the venom
of P. paulista has a naturally oxidised form of the peptide Paulistine,
which possesses a more compact structure due to the presence of a
disulphide bridge, in a conformation that causes hyperalgesia, appar-
ently favouring its interaction with receptors involved in lipid media-
tors metabolism at level of 5-lipoxygenase pathway (Fig. 15). The
present results do not permit to know if the naturally reduced form of
Paulistine has a different, or a similar biological activity as the Acm-
Paulistine; however, the in-vitro reduced and acetamidemethylated
form, which exists in a more expanded conformation, also causes
hyperalgesia, but this chemically modiﬁed form of Paulistine seems to
act at level of receptors involved with the prostanoid metabolism at
level of cyclooxygenase type II pathway (Fig. 15). This way, Paulistine
and Acm-Paulistine may be used as interesting tools to investigate the
mechanisms of pain and inﬂammation in future studies.
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